CN105431535A - 疟疾疫苗 - Google Patents

疟疾疫苗 Download PDF

Info

Publication number
CN105431535A
CN105431535A CN201480043750.5A CN201480043750A CN105431535A CN 105431535 A CN105431535 A CN 105431535A CN 201480043750 A CN201480043750 A CN 201480043750A CN 105431535 A CN105431535 A CN 105431535A
Authority
CN
China
Prior art keywords
virus
particle
antigen
malaria
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480043750.5A
Other languages
English (en)
Chinese (zh)
Inventor
上野隆司
赤畑涉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VLP Therapeutics Inc
Original Assignee
VLP Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VLP Therapeutics Inc filed Critical VLP Therapeutics Inc
Publication of CN105431535A publication Critical patent/CN105431535A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/193—Equine encephalomyelitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480043750.5A 2013-06-03 2014-06-02 疟疾疫苗 Pending CN105431535A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361830436P 2013-06-03 2013-06-03
US61/830436 2013-06-03
US201361906583P 2013-11-20 2013-11-20
US61/906583 2013-11-20
PCT/JP2014/065166 WO2014196648A1 (en) 2013-06-03 2014-06-02 Malaria vaccine

Publications (1)

Publication Number Publication Date
CN105431535A true CN105431535A (zh) 2016-03-23

Family

ID=52005658

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480043750.5A Pending CN105431535A (zh) 2013-06-03 2014-06-02 疟疾疫苗

Country Status (16)

Country Link
US (3) US9512190B2 (enExample)
EP (1) EP3004348B1 (enExample)
JP (1) JP6734651B2 (enExample)
KR (2) KR102494564B1 (enExample)
CN (1) CN105431535A (enExample)
AP (1) AP2015008926A0 (enExample)
AU (1) AU2014275772B2 (enExample)
BR (1) BR112015030229B1 (enExample)
CA (1) CA2913832C (enExample)
IL (1) IL242656B (enExample)
MX (1) MX386234B (enExample)
RU (1) RU2702163C2 (enExample)
SG (2) SG10201709917VA (enExample)
TW (1) TWI687442B (enExample)
WO (1) WO2014196648A1 (enExample)
ZA (1) ZA201508642B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109536464A (zh) * 2018-12-10 2019-03-29 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013122262A1 (en) 2012-02-16 2013-08-22 Vlp Therapeutics, Llc Virus like particle composition
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
JP6824154B2 (ja) 2014-08-08 2021-02-03 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子
SG11201701669PA (en) 2014-09-11 2017-04-27 Vlp Therapeutics Llc Flavivirus virus like particle
US10166281B2 (en) * 2015-09-04 2019-01-01 Vlp Therapeutics, Llc Method and composition for modulating immune response
WO2017048689A1 (en) * 2015-09-16 2017-03-23 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
WO2018193063A2 (en) 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites
SG11201910101SA (en) 2017-05-08 2019-11-28 Gritstone Oncology Inc Alphavirus neoantigen vectors
CA3086219A1 (en) 2017-12-20 2019-06-27 Vlp Therapeutics, Llc Alphavirus replicon particle
KR20200118029A (ko) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
CN114072516B (zh) 2019-05-30 2025-01-14 磨石生物公司 经修饰的腺病毒
CN115867658A (zh) 2020-04-17 2023-03-28 Vlp治疗公司 冠状病毒疫苗
AU2021264216A1 (en) 2020-04-30 2022-11-10 Vlp Therapeutics, Inc. Cytokine immunotherapy
JP2023541108A (ja) 2020-08-06 2023-09-28 グリットストーン バイオ インコーポレイテッド マルチエピトープワクチンカセット
KR20240107163A (ko) * 2021-11-22 2024-07-08 노바백스 에이비 말라리아를 치료 및 예방하기 위한 방법 및 조성물
WO2025064770A2 (en) * 2023-09-20 2025-03-27 La Jolla Institute of Immunology Alphavirus t cell epitopes, megapools and uses thereof
WO2025084276A1 (ja) * 2023-10-16 2025-04-24 Ｃｙｎ－Ｋバイオ株式会社 肥満の処置

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043399A2 (en) * 2002-11-13 2004-05-27 The United States Of America As Represented By The Secretary Of The Navy Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines
WO2012006180A1 (en) * 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
WO2012023995A1 (en) * 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0614465B1 (en) * 1991-11-16 1999-03-17 SMITHKLINE BEECHAM BIOLOGICALS s.a. HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG
SI1802336T1 (sl) * 2004-10-14 2012-01-31 Crucell Holland Bv Začetna/obnovitvena cepiva proti malariji
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
WO2008025067A1 (en) * 2006-08-30 2008-03-06 Hepgenics Pty Ltd Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
SG171828A1 (en) * 2008-11-26 2011-07-28 Us Gov Health & Human Serv Virus like particle compositions and methods of use
WO2011022002A1 (en) * 2009-08-18 2011-02-24 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
CN102695524B (zh) * 2009-09-18 2014-07-09 弗劳恩霍费尔美国股份有限公司 包含与植物病毒衣壳蛋白融合的靶蛋白的病毒样颗粒
WO2012106356A2 (en) * 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
WO2013122262A1 (en) * 2012-02-16 2013-08-22 Vlp Therapeutics, Llc Virus like particle composition
JP6824154B2 (ja) 2014-08-08 2021-02-03 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043399A2 (en) * 2002-11-13 2004-05-27 The United States Of America As Represented By The Secretary Of The Navy Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines
WO2012006180A1 (en) * 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
WO2012023995A1 (en) * 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AKAHATA ET AL.: "A VLP vaccine for epidemic Chikungunya virus protects non-human primates against infection", 《NAT MED.》 *
GREGSON ET AL.: "Phase I Trial of an Alhydrogel Adjuvanted Hepatitis B Core Virus-Like Particle Containing Epitopes of Plasmodium Falciparum Circumsporozoite Protein", 《PLOS ONE》 *
JOHNSON ET AL.: "AAB02517.1", 《GENBANK》 *
VOLK ET AL.: "ADG95942.1", 《GENBANK》 *
WEEDALL ET AL.: "AAW78190.1", 《GENBANK》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109536464A (zh) * 2018-12-10 2019-03-29 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用

Also Published As

Publication number Publication date
NZ714285A (en) 2021-02-26
CA2913832C (en) 2023-07-04
IL242656A (enExample) 2015-12-31
SG11201509614SA (en) 2015-12-30
RU2015155821A3 (enExample) 2018-06-05
ZA201508642B (en) 2022-03-30
RU2015155821A (ru) 2017-06-29
IL242656B (en) 2022-07-01
US20170035871A1 (en) 2017-02-09
BR112015030229A8 (pt) 2023-04-11
MX386234B (es) 2025-03-18
SG10201709917VA (en) 2017-12-28
TW201529605A (zh) 2015-08-01
KR20160016856A (ko) 2016-02-15
WO2014196648A1 (en) 2014-12-11
MX2015016627A (es) 2016-04-04
AU2014275772A1 (en) 2015-12-03
US20190351041A1 (en) 2019-11-21
EP3004348A4 (en) 2016-08-03
AU2014275772B2 (en) 2020-01-02
BR112015030229A2 (pt) 2017-08-22
KR102494564B1 (ko) 2023-01-31
US9512190B2 (en) 2016-12-06
TWI687442B (zh) 2020-03-11
KR20210116712A (ko) 2021-09-27
AP2015008926A0 (en) 2015-12-31
US20140363458A1 (en) 2014-12-11
JP2016521539A (ja) 2016-07-25
CA2913832A1 (en) 2014-12-11
EP3004348B1 (en) 2023-03-08
BR112015030229B1 (pt) 2023-04-18
RU2702163C2 (ru) 2019-10-04
EP3004348A1 (en) 2016-04-13
JP6734651B2 (ja) 2020-08-05

Similar Documents

Publication Publication Date Title
AU2014275772B2 (en) Malaria vaccine
Denis et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization
US9969986B2 (en) Virus like particle comprising modified envelope protein E3
TWI695842B (zh) 類黃熱病毒粒子
US10385101B2 (en) Virus like particle comprising modified envelope protein E3
MX2014009916A (es) Composicion de particula tipo virus.
CN105358683A (zh) 包含pd-1抗原或pd-1配体抗原的病毒样颗粒
CN110612118A (zh) 用于引起针对hbv的免疫应答的病毒样粒子
HK1206366A1 (en) Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
Verma et al. Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB
EP4415748A1 (en) Multiepitope self-assembled nanoparticle vaccine platform (msn-vaccine platform) and uses there of
OA17590A (en) Malaria Vaccine
NZ714285B2 (en) Malaria vaccine
Jelínková et al. An Epitope-based Malaria Vaccine Targeting the Junctional Domain of Circumsporozoite Protein
CN118019754A (zh) 诱导pres特异性中和抗体的hbv疫苗
JPWO2015133467A1 (ja) Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Delaware, USA

Applicant after: VLP treatment Co.

Address before: Delaware, USA

Applicant before: VLP THERAPEUTICS, LLC

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20160323

RJ01 Rejection of invention patent application after publication